This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More
Are Google, Facebook and Alibaba More Dangerous Than the NSA?

The question isn’t easy to answer, says first amendment scholar and University of Chicago Professor Geoffrey Stone.

Tony Robbins: Best Investors Take Least Risk for Largest Rewards

The world's best investors take the least amount of risk for the largest rewards, said Tony Robbins, author of 'Money: Master The Game'.

Shares of GameStop Plunge On Lower Revenue, Delayed Game Release

Shares of GameStop plunged on Friday after a disappointing earnings report on Thursday, making it TheStreet's move of the day.

Tony Robbins: Carl Icahn, Ray Dalio Are My Top Fund Manager Choices

Achieving genuine financial freedom only takes seven steps and is far less complicated than people believe, said Tony Robbins, author of 'Money: Master The Game.'

Real Money Previews

Jim Cramer on His Dad: ‘Our Last Day Together Was Our Best One’

A tribute to Ken Cramer, or 'Pop', father of TheStreet.com founder, 'Jimmy'.

Jim Cramer on the Stock Market: Thoughts on Foolish Groupthink

The latest example: Reams of wrongheaded hedge-fund short plays off the Ebola crisis.

Watch Out! These 'Torpedo' Stocks Could Sink Your Portfolio

It's worth paying attention to these potential portfolio killers.

Mad Money Recap

'Mad Money' Lightning Round: I'll Take Popeyes Over Wendy's

Cramer can't recommend Dynavax Technologies but wants you to hold Noble Energy.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to find the stocks he and Stephanie Link think could be HUGE winners. Click here to see them for FREE.

Stock Ideas

Time to Sell These 5 'Toxic' Stocks: Bitauto Holdings and More

For investors looking to buy one of these positions, it makes sense to wait for more favorable technical conditions (and a lower share price) before piling in.

5 Earnings Short-Squeeze Plays: Workday, Trina Solar and More

You only need to find a few short-squeeze plays to juice your annual returns.

Must-See Charts: How to Trade IBM, Applied Materials and More

Skilled technical traders can bank gains as much as 90% of the time.

5 Stocks With Big Insider Trading: Groupon, Jive Software and More

Insiders usually buy their own shares for one reason: They think the stock is a bargain and has tremendous upside.

5 Hated Short-Squeeze Stocks Ready to Pop: Burger King and More

Shorting in U.S. stocks is the highest it's been since September 2008. Investors hate stocks right now.

MainStreet

Obama’s Immigration Action May Unleash Environmental and Worker Health Claims

Industries that rely on undocumented immigrant workers might have to budget over coming years for an uptick in claims for environmental and safety violations.

Meet The Moneyman Behind Florida’s Amendment 2 Campaign: Bob Morgan

Analysis of Florida's medical marijuana vote - the only state reform campaign to "lose" in 2014 by winning a majority.

New Study Indicates Long-term Effects of Weed Use on Brain, Dire Implications for Pot Proponents

A report published in the prestigious Proceedings of the National Academy of Sciences is bad news for weed legalization proponents.

Apple Relabels Free Apps in an Attempt To Avoid Future Lawsuits

The iTunes store has changed the label for unpaid apps to reflect the reality that these days most so-called Free apps are nothing of the sort.

Massachusetts Approves Sick Leave Law--Guarantees Some Businesses Paid Sick Time

The Commonwealth joins Connecticut and California as the third state in the nation to mandate paid sick leave.

Biotech

Biotech Stock Mailbag: Northwest Bio, Celldex, Puma, MannKind

Biotech columnist Adam Feuerstein answers readers' questions about health care.

Royalty Pharma's $3.3 Billion Transaction is Bullish for Vertex Pharma

The $3.3 billion paid by Royalty Pharma to the Cystic Fibrosis Foundation to acquire royalty rights to Vertex Pharmaceuticals' cystic fibrosis drugs suggests investors are under-estimating peak sales.

Cramer: Agios Pharmaceuticals' Leukemia Drug Pushing Stock 'Much Higher'

TheStreet's Jim Cramer says Agios Pharmaceuticals' positive Phase 1 data for its leukemia treatment is impressive. As a result, shares are going higher despite doubling since July.

Beyond Wall St.

Deal News

Trouble in Casinoland: Caesars, Revel, Trump Entertainment Resorts

This week has been jam-packed with new developments from some of the troubled casino operators we're watching: Caesars Entertainment Corp., Revel AC Inc., and Trump Entertainment Resorts Inc.

Australian Manufacturing Company Orica Sells Its Chemical Business to Blackstone Group

After marketing its chemical business for more than a year, Australian manufacturing company Orica Ltd. is selling the unit to funds advised by Blackstone Group LP.

Facebook's $2 Billion Oculus Play Still a Virtual Reality

Though Sony and Google have followed suit, a dearth of VR content limits the technology's commercial use.

TheStreetTV
Spin Space

Jim Cramer

Dicker/Cramer: 'Oil's Endless Bid' Takes a Long Holiday

Dan Dicker, Energy contributor to TheStreet, talks to Jim Cramer about how under-appreciated financial inputs have impacted oil's fast drop in price.

Herb Greenberg

Greenberg: How Hertz Fooled So Many Hedge Fund Managers

But suing Audit Integrity wasn't such a good idea.

Stephanie Link

Dicker/Link: Tubular Bells Offshore Project Begins Production - but No Reason Yet to Invest

Dan Dicker talks with Stephanie Link, co-portfolio director of Action Alerts, about the beginnings of production of a $2.3 billion offshore project co-owned by Hess and Chevron.

Chris Ciaccia

Intel's Mobile Future Seems on Track After Analyst Day: What Wall Street's Saying

Intel shares tacked on gains following a sharp run-up after the company held its analyst day, announcing 2015 guidance, soothing investors' about the future of the world's largest ...

Adam Feuerstein

Biotech Stock Mailbag: Northwest Bio, Celldex, Puma, MannKind

Biotech columnist Adam Feuerstein answers readers' questions about health care.

Dan Freed

Are Google, Facebook and Alibaba More Dangerous Than the NSA?

The question isn’t easy to answer, says first amendment scholar and University of Chicago Professor Geoffrey Stone.

Ted Reed

Delta Order Affirms the Age of the Airbus A350 Is Approaching

The Airbus A350 had a good week as Delta announced an order and Qatar announced the timing for the first delivery.

Leon Lazaroff

Aereo May Be Dead, But Over-The-Top Television Is Just Beginning

Aereo's bankruptcy brings to an end a company that filled the public's demand for choice and mobility. Another provider would be wise to acquire its technology.

Submit an article to us!
DOW 17,810.06 +91.06 0.51%
S&P 500 2,063.50 +10.75 0.52%
NASDAQ 4,712.97 +11.1030 0.24%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs